55.96

1.04% -0.59

After Hours: 55.95 -0.010 -0.02%

Ionis Pharmaceuticals Inc (IONS)

Overview News Price History Option Chain Financials Discussions Forecast

Ionis Pharmaceuticals Inc stock is traded at $55.96, with a volume of 2.58M. It is down -1.04% in the last 24 hours and down -31.07% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Previous Close:

$56.55

Open:

$56.925

24h Volume:

2.58M

Relative Volume:

0.96

Market Cap:

$9.25B

Revenue:

$1.06B

Net Income/Loss:

$-326.58M

P/E Ratio:

-26.62

EPS:

-2.1022

Net Cash Flow:

$-977.73M

1W Performance:

+5.68%

1M Performance:

-31.07%

6M Performance:

-31.87%

1Y Performance:

+32.47%

1-Day Range:

$55.79

$57.09

1-Week Range:

$50.01

$57.48

52-Week Range:

$40.03

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name

Ionis Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

(760) 931-9200

Address

2855 GAZELLE COURT, CARLSBAD, CA

Employee

1,402

Twitter

@ionispharma

Next Earnings Date

2026-07-29

Latest SEC Filings

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IONS Ionis Pharmaceuticals Inc	55.96	9.35B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Apr-10-26	Resumed	Raymond James	Outperform
Jan-28-26	Resumed	Barclays	Overweight
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-26-25	Upgrade	Goldman	Sell → Neutral
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight
Apr-07-25	Initiated	H.C. Wainwright	Buy
Mar-31-25	Initiated	Redburn Atlantic	Neutral
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-16-24	Resumed	Jefferies	Buy
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral
Sep-29-23	Initiated	Raymond James	Strong Buy
Jul-31-23	Upgrade	Citigroup	Neutral → Buy
Jun-07-23	Resumed	Piper Sandler	Overweight
May-04-23	Upgrade	Citigroup	Sell → Neutral
Mar-21-23	Initiated	Bernstein	Underperform
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-09-22	Resumed	Morgan Stanley	Overweight
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-31-22	Resumed	Piper Sandler	Overweight
Mar-01-22	Initiated	Citigroup	Sell
Mar-01-22	Initiated	Guggenheim	Buy
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight
Dec-16-20	Initiated	UBS	Sell
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform
Sep-14-20	Resumed	JP Morgan	Neutral
Sep-02-20	Initiated	The Benchmark Company	Hold
Jun-01-20	Resumed	Oppenheimer	Outperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
Mar-05-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
Nov-07-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Sep-10-19	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-08-18	Reiterated	Stifel	Hold
Aug-07-18	Reiterated	Stifel	Hold
May-08-18	Downgrade	Evercore ISI	Outperform → In-line
Oct-06-17	Resumed	Goldman	Sell
Aug-17-17	Initiated	Evercore ISI	Outperform
Aug-09-17	Reiterated	Stifel	Hold
Mar-10-17	Downgrade	Goldman	Neutral → Sell
Dec-28-16	Reiterated	BMO Capital Markets	Outperform
Dec-27-16	Reiterated	Leerink Partners	Mkt Perform

View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

12:14 PM

Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review

12:14 PM

05:22 AM

Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews

05:22 AM

Jul 25, 2026

Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView

Jul 25, 2026

Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView

Jul 25, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire

Jul 25, 2026

Jul 24, 2026